Natural killer (NK) cell activity is a cell-mediated cytotoxic function expressed by peripheral blood mononuclear cells of most normal individuals.' Although the precise role of NK activity in vivo is debated, current evidence suggests that it may be important for a variety of normal functions, including inhibition of tumour growth or spread, control of certain viral infections, and immunoregulation.' 2 Diminished NK cytotoxicity has been described in several disease states, including systemic lupus erythematosus (SLE),3-6 but the significance of this finding for disease expression is not known. Recently it has been shown that the diminished NK cell function in patients with SLE may be due in part to circulating inhibitory factors, as sera from patients with SLE can inhibit the NK activity of peripheral blood mononuclear cells from normal individuals.7 8 Interestingly, sera from patients with active SLE also often contain interferon (IFN),9 " a potent stimulator of NK activity." 12 To assess the relationship between inhibition of NK activity by sera from patients with SLE and clinical disease activity, as well as the occurrence of IFN in these sera, the present study was undertaken. The Interferon assay. A previously described,"0 microtitre plaque-reduction assay for IFN was used, The clinical disease activity, therapeutic regimen, and level of serum-mediated inhibition of NK activity of each patient studied are shown in Table 1 . With unfractionated mononuclear cells from normal individuals as effectors, the mean inhibition of NK activity by sera from patients with active disease was 32 + 4% versus 15 ± 7% by sera from patients with inactive disease (Fig. 1) . These levels of inhibition are significantly different from each other (p<O005) and from results obtained with control sera from normal individuals (p<0-001 and p<0025, respectively).
When the studies were repeated with lymphocyte-enriched populations from normal indi- Several sera from patients with active disease only minimally inhibited NK activity. As IFN is a potent stimulator of NK activity and is known to be present in sera from patients with SLE, quantitation of IFN in several of these serum samples was undertaken to determine if its presence might explain these results. Of 11 sera assayed from patients with active disease IFN was found in 7. Of these, 6 inhibited MNmediated NK activity. Indeed, the sera containing IFN were among the most inhibitory sera examined. Of serum samples from patients with active disease those containing IFN caused a mean inhibition of MN-mediated NK activity of 39 ± 8% compared with a mean inhibition of 20 ± 5% for sera lacking measurable IFN (0 1>p>0 05).
Discussion
Diminished NK cell activity has been reported in patients with SLE,'-6 but neither the mechanism responsible for, nor the significance of, this observation is known. Sera from patients with SLE have been shown to inhibit NK activity,7 8 suggesting a role for humoral factors in effecting this alteration. Other lines of evidence suggest that an intrinsic defect of NK cells from patients with SLE may also exist."5
The present study has shown that the ability of sera from patients with SLE to inhibit the NK activity of normal MN populations is correlated with the presence of clinically active disease. These data suggest that as patients become clinically active they produce a factor(s) which is able to inhibit NK cytotoxicity. In addition this study has shown that sera from patients with inactive SLE inhibit NK cytotoxicity mediated by unfractionated MN but not lymphocyte-enriched populations. The reasons for this observation are not known but may relate to effects of the sera from patients with SLE on monocytes present in the unfractionated preparations, with secondary inhibitory effects being exerted on the NK cells. In contrast, the sera from patients with active disease may be able to inhibit NK cells directly. Furthermore, inhibition of NK activity by sera from patients with active SLE was shown to be independent of the presence of corticosteroids in the sera.
As IFN is known both to be present in sera of patients with active SLE9 'O and to stimulate in a potent manner NK cell activity," 12 
